Johnson & Johnson Vision,* a global leader in eye health and part of Johnson & Johnson MedTech,** US Food & Drug Administration (FDA) clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens innovation, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL. The announcement comes during the 125th Annual AOA Congress and 54th Annual AOSA Conference: Optometry’s Meeting® 2022 in Chicago (June 15-18).
The new contact lenses were developed to provide all-day comfort and visual clarity,2.3 amidst feedback from eye care professionals and patients that today’s modern lifestyles, long hours and increased use of digital devices are taking a toll on eye comfort. A recent survey found the majority (71%) of eye care professionals are seeing patients who are experiencing eye discomfort related to increased screen-time,1 with young contact lens wearers spending an average of 9 hours per day in front of a screen,4,5,6 causing them to blink less and experience more dryness and eye fatigue.7,8,9
“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” said Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision.† As Pioneers in eye health, we’re leading with high science and deep clinical expertise to innovate for those moments that matter. ACUVUE® OASYS MAX 1-Day is the latest in our long heritage of leading-edge innovation and we look forward to bringing this solution for patients experiencing ever-demanding lifestyles and environments. ”
Available in spherical and multifocal, ACUVUE® OASYS MAX 1-Day contact lenses are designed to address multiple vision correction needs. They will be a premium range of daily disposable contact lenses designed for proven performance.2.3
The new lenses are anticipated to be made available in the US, Canada and several European countries in the autumn.
Be the first to learn about ACUVUE® OASYS MAX 1-Day Contact Lenses here: https://www.jnjvisionpro.com/oasys-max-family
About Johnson & Johnson Vision*
Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, has a bold ambition: to change the trajectory of eye health worldwide. Through their operating companies, they deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with Greatest Needs, they work in Collaboration to expand access to quality eye care, and are committed to helping people see better, connect better, and live better. Visit them at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson MedTech**
At Johnson & Johnson MedTech, they unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and Empower everyone to live their best lives possible. For more than a century, they have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, they continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.